Pharmaxis Releases Successful Results of Phase 1 Clinical Trial for Boehringer Ingelheim Partnered Drug PXS4728A
22nd
Sep 15
Release Date: 22/09/2015 12:00am
Pharmaceutical company Pharmaxis (ASX: PXS) today announced positive results for all primary and secondary endpoints from the phase 1 clinical trial of PXS-4728A, a drug that was recently acquired by Boehringer Ingelheim to develop as a treatment for cardiometabolic diseases such as Non‐Alcoholic Steatohepatitis (NASH). PXS-4728A is a highly selective inhibitor of an enzyme and adhesion protein (SSAO/VAP-1 encoded by the AOC3 gene) which reduces inflammation and oxidative stress.
Categories: News and Media